Consistent with our observation that the “Proliferative” subtype is enriched among patients with AFR genetic similarity, a retrospective study comparing outcomes with VEGF inhibitors in metastatic ccRCC found inferior outcomes in self-reported B patients though this was not statistically significant when controlling for International Metastatic RCC Database Consortium score (36). This evidence concerns the gene VEGFA and renal cell carcinoma.